ClinicalTrials.gg
CompletedNCT03404960ParpvaxUpdated Oct 10, 2025Results posted

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

A Phase 1/2 interventional study of Niraparib + Nivolumab and Niraparib + Ipilimumab in Pancreatic Adenocarcinoma, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by University of Pennsylvania · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs Niraparib with either Ipilimumab or Nivolumab on patients and their pancreatic cancer.

02

Conditions studied

  • Pancreatic Adenocarcinoma

Keywords

  • Platinum
  • chemotherapy
  • Niraparib
  • Ipilimumab
  • Nivolumab
  • Pancreatic adenocarcinoma
  • PARP inhibitor
  • Pancreatic ductal adenocarcinoma
  • DDR
  • PDAC
03

In context

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 233 are open to participants now.

Of its 159 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of pancreatic adenocarcinoma with locally advanced or disease
  2. ≥18 years of age
  3. Patients must be able to understand the study procedures and agree to participate in the study by providing written
  4. Patients must have received treatment with platinum-based (cisplatin, oxaliplatin or carboplatin) treatment for locally advanced or metastatic pancreatic cancer and have received a minimum of 16 weeks of therapy without evidence of disease progression based on the investigator's opinion. This does not have to be the patient's current treatment.

    • This requires at least stable imaging and a stable or decreasing tumor marker as applicable and as determined by the investigator.
    • If a patient has demonstrated a biochemical and imaging response to platinum therapy and has not progressed within 16 weeks of starting this therapy but had to discontinue platinum prior to 16 weeks for a legitimate medical reason (as determined by the investigator), the patient may still be considered for the trial
  5. Patients may have previously failed non-platinum containing therapy or may never have previously progressed on treatment

    • Discontinuation of the platinum component of the regimen for chemotherapy-related toxicity is permissible provided the patient has previously received at least 16 weeks of platinum-based therapy without evidence of disease progression ≤8 weeks after treatment with the platinum agent
  6. is not a requirement for study entry
  7. Female participant has a negative serum pregnancy test within 24 hours prior to taking study treatment if of and agrees to abstain from activities that could result in pregnancy from screening through 6 months after the last dose of study treatment, or is of nonchildbearing potential
  8. Male patient agrees to use an adequate method of starting with the first dose through 90 days after the last dose of study treatment
  9. Adequate organ function confirmed by the following laboratory values obtained ≤7 days prior to the first day of study therapy:

    • (ANC) ≥1.5 x 109/L
    • >100 x 109/L
    • ≥9g/dL
    • (AST) and alanine aminotransferase (ALT) ≤3 x (ULN); if liver metastases, then ≤5 x ULN
    • Total ≤1.5 x ULN; if liver metastases or metabolic disorder such as Gilbert's syndrome, then ≤2.5 x ULN.
    • Serum creatinine ≤1.5 x ULN or estimated (GFR) ≥45 mL/min using formula.
  10. Eastern Cooperative Oncology () performance status of 0 to 1.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with a PARP inhibitor, ipilimumab, nivolumab or other cytotoxic T-lymphocyte-associated protein (), PD-1 or PD-L1 inhibitor.
  2. Patients who have demonstrated resistance to platinum agents (e.g. oxaliplatin, cisplatin) are not eligible to participate in this study
  3. Clinical evidence of uncontrolled malabsorption and/or any other gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with the absorption of niraparib
  4. Acute infection requiring intravenous antibiotics, antiviral or antifungal agents during the 14 days prior to first dose of study therapy
  5. Patients will be excluded if they have an active, known or suspected disease, defined as: patients with a history of inflammatory bowel disease are excluded from this study, as are patients with a history of symptomatic autoimmune disease (e.g. rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis e.g. Wegener's Granulomatosis); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome).

    NOTE: Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.

  6. Has a history of interstitial lung disease or active, non-infectious pneumonitis
  7. Has received a within 4 weeks prior to the first dose of trial therapy (Note: seasonal influenza vaccines for injection are generally inactivated and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines and are not allowed
  8. For fertile patient (female able to become pregnant or male able to father a child), refusal to use effective during the period of the trial and:

    • Female patients refusing to use effective contraception for 6 months after the last dose of study drug.
    • Male patients refusing to use effective contraception for 90 days after the last dose of study drug.
  9. Received any systemic treatment for pancreatic cancer ≤14 days prior to first dose of therapy. Patients must not have had therapy administered ≤4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
  10. Patients will be excluded if they have a condition requiring systemic treatment with either (>10mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
  11. Patient has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
  12. Non-study related minor surgical procedure ≤5 days, or major surgical procedure ≤21 days, prior to the first dose of therapy; in all cases, patients must be sufficiently recovered and stable before treatment administration.
  13. Active drug or alcohol use or dependence that would interfere with study compliance.
  14. Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry into the study.
  15. Patient must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
  16. Patients must not be simultaneously enrolled in any therapeutic clinical trial
  17. Patients must not have had radiotherapy within 4 weeks of the first dose of study treatment
  18. Patients must not have a known to the components of niraparib or the
  19. Patients must not have received a transfusion ( or red blood cells) ≤ 4 weeks of the first dose of study treatment
  20. Patients must not be undergoing treatment for an active cancer at the time of randomization. Exceptions include: local therapies for skin cancers and hormonal therapies for breast or prostate cancer.
  21. Patients must not have a history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS), and must not test positive for HIV during study screening.
  22. Patients must not have known, symptomatic brain or
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Arm A

    Niraparib + Nivolumab

    Drug: Niraparib + Nivolumab

  • Experimental
    Arm B

    Niraparib + Ipilimumab

    Drug: Niraparib + Ipilimumab

Interventions

  • DrugNiraparib + Nivolumab

    Drug pages: Niraparib · Nivolumab

    Niraparib 200mg PO daily on days 1-28 of each 28-day cycle. Nivolumab 480mg IV day 1 of each cycle.

    Also known as: Arm A

  • DrugNiraparib + Ipilimumab

    Drug pages: Niraparib · Ipilimumab

    Niraparib 200mg PO daily on days 1-21 of each 21-day cycle. Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only.

    Also known as: Arm B

06

What researchers measure

Primary outcomes

  1. Rate of Progression-free Survival at 6 Months (PFS6)

    The PFS6 rate will be estimated using the Kaplan-Meier method, and the 95% confidence interval will be estimated from the Kaplan-Meier curve. The null hypothesis is that the PFS6 rate in this population of subjects is 44%. Progressive disease is defined as at least a 20% increase in the sum of all the longest diameter (LD) of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. Target lesions assessed according to RECIST v1.1.

    Time frame: 6 months after initiation of study therapy

Secondary outcomes

  1. Objective Response Rate (ORR) Per RECIST v.1.1 as Assessed by Radiology Review

    The proportion of patients who achieve a complete or partial response, as determined by RECIST

    Time frame: From first restaging assessment through completion of study treatment (maximum 42 months)

  2. Overall Survival (OS)

    Start of treatment to death due to any cause or last patient contact alive.

    Time frame: Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first

07

Results

Posted Jul 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
Started4645
Completed4440
Not completed25
Withdrew: Adverse event02
Withdrew: Rapidly declined before 1st follow-up scan02
Withdrew: Bowel obstruction01
Withdrew: Incorrect pathological diagnosis on internal review20

Outcome measures

PrimaryRate of Progression-free Survival at 6 Months (PFS6)

The PFS6 rate will be estimated using the Kaplan-Meier method, and the 95% confidence interval will be estimated from the Kaplan-Meier curve. The null hypothesis is that the PFS6 rate in this population of subjects is 44%. Progressive disease is defined as at least a 20% increase in the sum of all the longest diameter (LD) of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. The appearance of one or more new lesions is also considered progression. Target lesions assessed according to RECIST v1.1.

Time frame:
6 months after initiation of study therapy
Reported as:
Number · percentage of participants with PFS
Rate of Progression-free Survival at 6 Months (PFS6)
percentage of participants with PFSNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
Rate of Progression-free Survival at 6 Months (PFS6)20.6 (8.3 to 32.9)59.6 (44.3 to 74.9)
SecondaryObjective Response Rate (ORR) Per RECIST v.1.1 as Assessed by Radiology Review

The proportion of patients who achieve a complete or partial response, as determined by RECIST

Time frame:
From first restaging assessment through completion of study treatment (maximum 42 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per RECIST v.1.1 as Assessed by Radiology Review
Percentage of participantsNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
Objective Response Rate (ORR) Per RECIST v.1.1 as Assessed by Radiology Review7.7 (1.5 to 19.5)15.4 (5.9 to 30.5)
SecondaryOverall Survival (OS)

Start of treatment to death due to any cause or last patient contact alive.

Time frame:
Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first
Reported as:
Median · Months
Overall Survival (OS)
MonthsNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
Overall Survival (OS)13.2 (8.1 to 16.7)17.3 (12.8 to 21.9)

Adverse events

Collected over Adverse events were assessed from 6 months after initiation of study therapy. All-Cause Mortality was from Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent or until 5 years have passed, whichever occurs first.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib + Nivolumab (Arm A)7/46 (15.2%)20/46 (43.5%)46/46 (100%)
Niraparib + Ipilimumab (Arm B)5/45 (11.1%)15/45 (33.3%)44/45 (97.8%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
Platelet count decreasedInvestigations1/462/45
Rash maculo-papularSkin and subcutaneous tissue disorders0/462/45
Abdominal painGastrointestinal disorders2/460/45
Blood bilirubin increasedInvestigations2/460/45
PneumonitisRespiratory, thoracic and mediastinal disorders2/461/45
ColitisGastrointestinal disorders0/461/45
Duodenal ulcerGastrointestinal disorders0/461/45
Small intestinal obstructionGastrointestinal disorders0/461/45
FeverGeneral disorders1/461/45
Other: Acute cholangitisHepatobiliary disorders0/461/45
Most frequent other events
Showing 10 of 48
Most frequent other events
EventNiraparib + Nivolumab (Arm A)Niraparib + Ipilimumab (Arm B)
FatigueGeneral disorders13/4626/45
Aspartate aminotransferase increasedInvestigations12/4622/45
Platelet count decreasedInvestigations18/4621/45
AnemiaBlood and lymphatic system disorders10/4620/45
NauseaGastrointestinal disorders16/4620/45
Alanine aminotransferase increasedInvestigations10/4620/45
Abdominal painGastrointestinal disorders18/4612/45
Alkaline phosphatase increasedInvestigations14/4617/45
DiarrheaGastrointestinal disorders6/4612/45
HypomagnesemiaMetabolism and nutrition disorders8/4611/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years182341
>=65 years261743
Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Median68 (46 to 84)64 (48 to 81)66 (46 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female152035
Male292049
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American336
White383775
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Arm AArm BTotal
United States444084
08

Study locations

1 site
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, Karasic T, Tondon R, Onyiah C, Gosselin MK, Donze A, Domchek SM, Vonderheide RH. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol. 2022 Aug;23(8):1009-1020. doi: 10.1016/S1470-2045(22)00369-2. Epub 2022 Jul 7. PubMed 35810751 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Apr 2022, 50 months.

Results were first posted in Jul 2023, 1 year 2 months after primary completion. A results delay was requested in Mar 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2017
First posted
Jan 19, 2018
StartActual
Jan 31, 2018
Primary completionActual
Apr 5, 2022
CompletionActual
Oct 9, 2024
Results delay requested
Mar 21, 2023
Results first posted
Jul 3, 2023
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03404960
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Jan 31, 2018
Primary completion
Apr 5, 2022
Completion
Oct 9, 2024
Results posted
Jul 3, 2023
Last update
Oct 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Nivolumab · Ipilimumab

Start the discussion